Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)
China · Delayed Price · Currency is CNY 23.49
+0.28 (1.21%)
At close: Jun 12, 2026
SHA:688217 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 159.55 | 174 | 234.95 | 246.05 | 416.06 | 270.59 |
Other Revenue | 3.26 | 3.26 | 7.36 | 12.16 | 8.24 | 20.36 |
| 162.81 | 177.26 | 242.31 | 258.21 | 424.3 | 290.95 | |
Revenue Growth (YoY) | -28.73% | -26.84% | -6.16% | -39.14% | 45.83% | 2.11% |
Cost of Revenue | 44.26 | 47.95 | 62.84 | 70.56 | 166.6 | 78.83 |
Gross Profit | 118.55 | 129.31 | 179.47 | 187.65 | 257.7 | 212.12 |
Selling, General & Admin | 92.69 | 98 | 127.32 | 120.9 | 109.76 | 115.31 |
Research & Development | 51.14 | 53 | 62.47 | 69.8 | 64.43 | 68.64 |
Other Operating Expenses | 5.2 | 3.11 | 2.18 | 2 | 1.14 | 0.78 |
Operating Expenses | 167.22 | 168.11 | 198.62 | 197.73 | 184.88 | 185.09 |
Operating Income | -48.67 | -38.8 | -19.15 | -10.08 | 72.81 | 27.04 |
Interest Expense | -0.37 | -0.19 | -0.88 | -0.83 | -0.55 | -0.49 |
Interest & Investment Income | 4.68 | 4.63 | 4.79 | 6.49 | 4.74 | 4.08 |
Currency Exchange Gain (Loss) | -1.02 | -1.02 | 0.66 | 0.84 | 4.69 | -1.54 |
Other Non Operating Income (Expenses) | 0.1 | 0.08 | -0.26 | -0.58 | -0.35 | -0.75 |
EBT Excluding Unusual Items | -45.27 | -35.3 | -14.85 | -4.15 | 81.34 | 28.34 |
Impairment of Goodwill | -7.61 | -7.61 | -14.31 | -7.5 | -13.39 | - |
Gain (Loss) on Sale of Investments | 1 | 1.09 | 0.87 | 0.33 | 0.61 | 2.09 |
Gain (Loss) on Sale of Assets | -0.24 | 0.13 | 0.12 | 0.84 | -0.01 | -0.1 |
Asset Writedown | -17.79 | -17.82 | -2.37 | -0.14 | -0.77 | - |
Other Unusual Items | 9.37 | 8.79 | 2.05 | 1.22 | 3.7 | 12.12 |
Pretax Income | -60.54 | -50.73 | -28.47 | -9.4 | 71.48 | 42.45 |
Income Tax Expense | 8.61 | 9.69 | -2.57 | -4.6 | 5.56 | 2.37 |
Earnings From Continuing Operations | -69.15 | -60.42 | -25.91 | -4.8 | 65.92 | 40.08 |
Minority Interest in Earnings | 10.43 | 10.04 | 10.14 | 12.74 | -25.45 | 7.25 |
Net Income | -58.72 | -50.38 | -15.76 | 7.93 | 40.47 | 47.33 |
Net Income to Common | -58.72 | -50.38 | -15.76 | 7.93 | 40.47 | 47.33 |
Net Income Growth | - | - | - | -80.41% | -14.49% | 22.26% |
Shares Outstanding (Basic) | 55 | 55 | 56 | 57 | 55 | 50 |
Shares Outstanding (Diluted) | 55 | 55 | 56 | 57 | 55 | 50 |
Shares Change (YoY) | -3.04% | -1.67% | -0.61% | 2.17% | 11.28% | 19.69% |
EPS (Basic) | -1.06 | -0.91 | -0.28 | 0.14 | 0.73 | 0.95 |
EPS (Diluted) | -1.06 | -0.91 | -0.28 | 0.14 | 0.73 | 0.95 |
EPS Growth | - | - | - | -80.82% | -23.16% | 2.15% |
Free Cash Flow | 11.27 | 18.79 | 20.57 | -64 | -33.5 | -17.63 |
Free Cash Flow Per Share | 0.20 | 0.34 | 0.36 | -1.13 | -0.60 | -0.35 |
Dividend Per Share | - | - | - | 0.180 | - | - |
Gross Margin | 72.82% | 72.95% | 74.07% | 72.67% | 60.73% | 72.91% |
Operating Margin | -29.89% | -21.89% | -7.90% | -3.91% | 17.16% | 9.29% |
Profit Margin | -36.06% | -28.42% | -6.51% | 3.07% | 9.54% | 16.27% |
Free Cash Flow Margin | 6.92% | 10.60% | 8.49% | -24.79% | -7.90% | -6.06% |
EBITDA | -15.48 | -3.81 | 23.04 | 29.15 | 103.68 | 60.04 |
EBITDA Margin | -9.51% | -2.15% | 9.51% | 11.29% | 24.44% | 20.64% |
D&A For EBITDA | 33.19 | 34.99 | 42.2 | 39.23 | 30.86 | 33 |
EBIT | -48.67 | -38.8 | -19.15 | -10.08 | 72.81 | 27.04 |
EBIT Margin | -29.89% | -21.89% | -7.90% | -3.91% | 17.16% | 9.29% |
Effective Tax Rate | - | - | - | - | 7.78% | 5.58% |
Revenue as Reported | 162.81 | 177.26 | 242.31 | 258.21 | 424.3 | 290.95 |